Profound Medical Corp. and Philips Sell TULSA-PRO™ System to UCL and UCLH

Print
| Source: Profound Medical Inc.

TORONTO, June 20, 2016 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSXV:PRN) ("Profound" or "the Company"), an emerging medical device company focused on prostate care, today announced that it and Royal Philips (“Philips”) have jointly sold a TULSA-PROTM system in the United Kingdom to UCL (University College London) and University College London Hospitals NHS Foundation Trust (UCLH).

This marks the first sale under the Company’s recent collaboration with Philips, following Profound’s receipt of CE Mark approval in April 2016.

Professor Mark Emberton, Dean, UCL Faculty of Medical Sciences and Professor of Interventional Oncology, is well-known for his thought leadership on novel imaging techniques and minimally-invasive treatments in Europe.

Prof. Emberton, who also holds a post as an honorary consultant urologist at UCLH, commented, “We are delighted to be able to offer the TULSA procedure to our patients at UCLH in the very near future. This innovative technology is a compelling therapeutic option for prostate ablation in patients with localized prostate cancer. I am intrigued at investigating its promising versatility, in the course of time, as a focal therapy option.”

Steve Plymale, Profound Medical CEO, added, “We are pleased to complete the second sale of our TULSA-PRO system. We anticipate that UCLH will become an active centre for TULSA procedures in the United Kingdom. Our partnership with such luminary institutions such as UCL and UCLH will help us broaden awareness, acceptance and adoption of TULSA-PRO amongst clinicians and patients in Europe.”

TULSA-PRO is a unique technology that combines real-time Magnetic Resonance Imaging (MRI) with transurethral robotically-driven ultrasound and closed-loop thermal feedback control providing a highly precise prostate treatment tailored to patient-specific anatomy. It has demonstrated accurate and precise ablation of malignant prostate tissue, while providing a favourable safety profile, with low rates of serious or long-term adverse events.

About Profound Medical Corp.

Profound is a Canadian medical device company that developed a unique and minimally invasive procedure to ablate malignant prostate tissue. The Company’s novel technology combines real-time Magnetic Resonance imaging with transurethral, robotically-driven therapeutic ultrasound and closed-loop thermal feedback control. It provides a highly precise treatment tailored to patient-specific anatomy and pathology. This method of prostate ablation offers short treatment times and low morbidity, allowing for fast patient recovery. For more information, visit www.profoundmedical.com 

Forward-Looking Statements

This release includes forward-looking statements regarding Profound and its business which may include, but is not limited to, the expectations regarding the efficacy of Profound’s technology in the treatment of prostate cancer. Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "is expected", "expects", "scheduled", "intends", "contemplates", "anticipates", "believes", "proposes" or variations (including negative variations) of such words and phrases, or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Such statements are based on the current expectations of the management of Profound. The forward-looking events and circumstances discussed in this release, may not occur by certain specified dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting the company, including risks regarding the pharmaceutical industry, economic factors, the equity markets generally and risks associated with growth and competition. Although Profound has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and Profound undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise, other than as required by law.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contacts

Media:

Rebecca von Goetz
Senior Marketing & Communications Specialist
Profound Medical Corp.
rvongoetz@profoundmedical.com
T: 647.476.1350, Ext. 426
C: 416.917.8650

Investors:

Stephen Kilmer
Investor Relations
skilmer@profoundmedical.com
T: 647.872.4849